Clinical trials: Nerve Sheath Tumors
Neurofibromatosis 1, Social Skills
Open Trial of Telehealth Group for Improving Peer Relationships (PEERS) in NF1
This is an open trial of the UCLA PEERS protocol delivered via Telehealth with teens with neurofibromatosis type 1 whose parents report that they have difficulty making and keeping friends.
- Trial name
- NCT04856514
- Testing
- PEERS
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Milwaukee
Cutaneous Neurofibromas
First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas
The purpose of this study is to determine whether multiple cutaneous neurofibromas in patients with neurofibromatosis type 1 can be removed with an erbium-YAG-laser.
- Trial name
- NCT00921037
- Testing
- Erbium-YAG laser vaporization
- Where
- Austria
- Volunteers
- 12 people
- Sponsor
- Medical University of Vienna
Whole Body Imaging, Magnetic Resonance Imaging
Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis
Whole body MRI will be performed in patients with neurofibromatosis Type 1 PURPOSE 1: To determine the total tumor load (neurofibroma) and to diagnose plexiform neurofibromas or malignant peripheral nerve sheath tumors.
- Conditions
- Whole Body Imaging, Magnetic Resonance Imaging, Neurofibromatosis 1, Diffusion Magnetic Resonance Imaging
- Trial name
- NEFIMAR (NCT01777451)
- Testing
- Additional imaging or surgery
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Neurofibromatosis Type 2, Vestibular Schwannoma
Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)
This is an adaptive platform-basket trial that aims to evaluate the safety and efficacy of multiple novel agents and combination therapies in patients with NF2-related schwannomatosis (NF2-SWN).
- Conditions
- Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma
- Trial name
- PRIME-NF2 (NCT07713745)
- Testing
- Selumetinib 25mg/m2, Luvometinib, Serplulimab
- Where
- 5 sites in China
- Volunteers
- 200 people
- Sponsor
- Beijing Tiantan Hospital
Vestibular Schwannoma
Response Prediction After GKS in Patients With Vestibular Schwannoma Using DCE MR Imaging
Response Prediction after Gamma Knife Surgery (GKS) in Patients with Vestibular Schwannoma using Dynamic Contrast-Enhanced (DCE) MR Imaging
- Trial name
- NCT03097822
- Volunteers
- 90 people
- Sponsor
- Seoul National University Hospital
Neuroma, Human Forefoot
Morton's Neuroma: Manipulation Versus Steroid Injection
The aim of this study is to establish which of two treatment options is the preferred intervention in the treatment of Morton's Neuroma. A randomised controlled trial shall be performed.
- Trial name
- NCT02304094
- Testing
- methylprednisolone, Manual manipulation
- Where
- United Kingdom
- Volunteers
- 64 people
- Sponsor
- Queen Margaret University
Vestibular Schwannoma, Brain Metastases
Protocol for Evaluating a Planning Algorithm for Gamma Knife Radiosurgery
The process of developing Gamma Knife radiosurgery treatment plans is today very dependent on the level of human expertise resulting in a great heterogeneity of the intrinsic qualities of the treatment planning and the quality of…
- Conditions
- Vestibular Schwannoma, Brain Metastases, Para-optic Meningioma
- Trial name
- SPEED (NCT03520829)
- Testing
- Intuitive Plan
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Neurofibromatosis Type 2
Doxycycline in Cutaneous Schwannoma (NF2)
In this research study the investigators want to learn more about an alternate, local treatment for skin schwannomas. Specifically, local doxycycline intra-tumoral injection will be performed as a potential treatment for…
- Trial name
- NCT05521048
- Testing
- Doxycycline Injection [Doxy]
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas, Histiocytic Neoplasm
Individual Patient Compassionate Use of Mirdametinib
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.
- Conditions
- Neurofibromatosis Type 1-Associated Plexiform Neurofibromas, Histiocytic Neoplasm, Other MAP-K Pathway Driven Diseases
- Trial name
- NCT05028166
- Testing
- Mirdametinib (MEK Inhibitor)
- Where
- 2 sites in United States, Germany
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Plexiform Neurofibromas (PN)
Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children
The goal of this study is to compare the efficacy and safety of low-dose and internationally recommended standard dose of selumetinib in the treatment of plexiform neurofibromas in Chinese children.
- Trial name
- LS-NF1PNs (NCT06763315)
- Testing
- Selumetinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- West China Hospital
Prostate Cancer
Effect of Anesthetic Method on Optic Nerve Sheath Diameter in Patients Undergoing RALP
The purpose of this study was to evaluate the effect of anesthetic method on the optic nerve sheath diameter in patients undergoing robot-assisted laparoscopic prostatectomy.
- Trial name
- NCT03529643
- Testing
- Dexmedetomidine, Without dexmedetomidine
- Where
- South Korea
- Volunteers
- 128 people
- Sponsor
- Asan Medical Center
HIV, Brain Tumors
Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments
Background: People with chronic illness often are at risk for developing neurobehavioral problems due to effects of the disease or associated treatments.
- Conditions
- HIV, Brain Tumors, Neurofibromatosis Type 1
- Trial name
- NCT01445314
- Where
- United States
- Volunteers
- 598 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including, Sickle Cell Disease
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Cell-free fetal DNA (cffDNA) is present in the maternal blood from the early first trimester of gestation and makes up 5%-20% of the total circulating cell-free DNA (cfDNA) in maternal plasma.
- Conditions
- Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including, Sickle Cell Disease, Cystic Fibrosis, Fragile X Syndrome
- Trial name
- DANNIgene (NCT06147414)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 550 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sporadic Acoustic Neuromas, Useful Hearing
Cyberknife Radiosurgery for Patients With Neurinomas
Most vestibular schwannomas are benign and slow-growing. Based on that fact, conservative management with serial imaging is a viable alternative.
- Trial name
- ACOUNEU (NCT02055859)
- Testing
- Radiosurgery
- Where
- Italy
- Volunteers
- 108 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Sarcoma, Synovial Sarcoma
Sorafenib and Dacarbazine in Soft Tissue Sarcoma
The purpose of this study is to find out what effects, good and/or bad, the combination of sorafenib and dacarbazine has on sarcoma. Recurrent sarcoma is difficult to treat.
- Conditions
- Sarcoma, Synovial Sarcoma, Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor
- Trial name
- NCT00837148
- Testing
- Sorafenib and Dacarbazine
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasms, Nerve Tissue, Neurofibromatosis 1
Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)
Background: Gastrointestinal stromal tumors (GIST) can cause serious medical problems. The only known treatment is surgery. But completely removing a GIST tumor with surgery is often not possible.
- Conditions
- Neoplasms, Nerve Tissue, Neurofibromatosis 1, Heredodegenerative Disorders, Nervous System, Peripheral Nervous System Diseases
- Trial name
- NCT03109301
- Testing
- Selumetinib (AZD6244 hyd sulfate) 50mg/dose, Selumetinib (AZD6244 hyd sulfate) 25mg/m2
- Sponsor
- National Cancer Institute (NCI)
Vestibular Neuronitis, Vestibular Neuronitis, Bilateral
Recovery of Visual Acuity in People With Vestibular Deficits
The purpose of this study is to determine whether exercises relieve the symptoms of dizziness and imbalance in people with vestibular deficits and improves the ability to see clearly during head movements.
- Conditions
- Vestibular Neuronitis, Vestibular Neuronitis, Bilateral, Vestibular Schwannoma
- Trial name
- NCT00411216
- Testing
- Control exercises, gaze stabilization exercises
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Emory University
Pediatric Solid Tumor, Osteosarcoma
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old…
- Conditions
- Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma, Neuroblastoma
- Trial name
- NCT04897321
- Testing
- Fludarabine, Cyclophosphamide, MESNA
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- St. Jude Children's Research Hospital
Neoplasms, Nervous System Disease
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Background: Neurofibromatosis type II (NF2) is associated with tumors of the nerves, brain, and spinal cord. Most people with NF2 develop vestibular schwannomas, or tumors on the hearing and balance nerves.
- Conditions
- Neoplasms, Nervous System Disease, Vestibular Disease
- Trial name
- NCT01222728
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Vestibular Schwannoma, NF2
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Tumors can grow on the auditory nerves and can cause hearing loss. A common type of tumor that does this is a vestibular schwannoma (VS), or acoustic neuroma. These tumors are not cancerous. Most often, people have only one VS.
- Conditions
- Vestibular Schwannoma, NF2, Neurofibromatosis 2, Acoustic Neuroma
- Trial name
- NCT00863122
- Testing
- lapatinib
- Where
- 7 sites in United States
- Volunteers
- 26 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins